Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idarubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | S100A4 | P26447 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idarubicin SCHEMBL13488561 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL16609956 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL12257447 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL15159345 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL13575798 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL18738468 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL16606206 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL7029978 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL20541733 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL10061859 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 146821 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075497-A | Use of NLRP3 agonist for tumor treatment | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075672-A | Application of hD1R protein in preparation of medicine for treating AML | — | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-4973674-A | GLYCOSIDES, ANTICANCER, ANTITUMOR | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-11-27 | — | — | US | claimed |
| EP-0398305-A2 | Anthracycline conjugates having a novel linker and methods for their production | Bristol-Myers Squibb Company (US) | 1990-11-22 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| US-4950738-A | ANTICARCINOGENS | CYTOGEN CORPORATION (US) | 1990-08-21 | — | — | US | claimed |
| EP-0335369-A2 | New anthracycline derivatives and processes for the preparation of the same | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1989-10-04 | — | — | EP | claimed |
| EP-0328147-A2 | Anthracycline immunoconjugates having a novel linker and methods for their production | Bristol-Myers Squibb Company (US) | 1989-08-16 | — | — | EP | claimed |
| WO-1988009823-A1 | AMINE DERIVATIVES OF ANTHRACYCLINE ANTIBIOTICS AND ANTIBODY CONJUGATES THEREOF | CYTOGEN CORPORATION (US) | 1988-12-15 | — | — | WO | claimed |
| EP-0294294-A2 | Amine derivatives of anthracycline antibiotics | CYTOGEN CORPORATION (US) | 1988-12-07 | — | — | EP | claimed |
| CN-88101810-A | IMMUNOGLOBULIN CONJUGATES | — | 1988-11-09 | — | — | CN | claimed |
| US-4534971-A | MIXING IN AQUEOUS SOLUTION;ANTITUMOR AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1985-08-13 | — | — | US | claimed |